FMC Corporation — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. FMC is a global agricultural sciences company operating as one segment, selling crop-protection products and plant-health solutions across four regions.
Financial performance
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $4.487 billion | $5.802 billion |
| Gross margin | $1.831 billion; 40.8% of revenue | $2.327 billion; 40.1% of revenue |
| Operating profit | $555.6 million | $1.144 billion |
| Net income attributable to FMC stockholders | $1.322 billion; diluted EPS $10.53 | $736.5 million; diluted EPS $5.81 |
| Adjusted after-tax earnings attributable to stockholders | $474.5 million | $938.4 million |
| Adjusted EBITDA | $978.0 million | $1.407 billion |
| Cash from continuing operating activities | $(300.3) million | $660.0 million |
| Free cash flow (non-GAAP) | $(524.3) million | $514.2 million |
Revenue fell approximately 23% (22% excluding foreign currency), primarily from channel inventory destocking and lower volumes. Sales declined in every region: Latin America 33%, Asia 21%, North America 16%, and EMEA 14%. In 2023’s fourth quarter, revenue was $1.146 billion versus $1.622 billion a year earlier; income from continuing operations was $1.154 billion, largely reflecting tax benefits rather than operating recovery.
Gross margin dollars declined about 21%; the reported margin rate was 40.8%, compared with 40.1%. Excluding the $25.8 million Argentina PAIS tax charge, FMC reported a 41.4% margin rate. Adjusted EBITDA fell about 30%, as volume pressure outweighed cost and pricing benefits. R&D expense rose 5% to $328.8 million; SG&A declined 5% to $734.3 million.
Liquidity, debt and capital
- Cash and cash equivalents were $302.4 million, down from $572.0 million. Total debt was $3.958 billion, up from $3.274 billion; $934.0 million was classified as current debt and current maturities.
- Commercial paper outstanding was $739.5 million at an average rate of 6.11%. Remaining revolver borrowing capacity was $1.009 billion. FMC reported compliance with debt covenants at year-end.
- Credit-agreement amendments provide temporary covenant relief, with leverage and interest-coverage limits stepping back toward prior levels through September 2025. Share repurchases are prohibited through September 30, 2025, except for equity-plan-related repurchases.
- FMC issued $1.5 billion of senior notes in May 2023, with maturities in 2026, 2033 and 2053. It paid $290.5 million in dividends during 2023.
Changes, outlook and management commentary
- Management attributed the downturn to distributors, retailers and growers reducing purchases from late Q2 through year-end as supply security improved and inventory carrying costs increased. FMC said grower consumption remained steady, but channel destocking sharply reduced shipments and cash flow.
- Products launched in the prior five years generated about $590 million, or 14% of revenue. Diamides Rynaxypyr and Cyazypyr generated approximately $1.8 billion combined, about 39% of revenue, and outperformed the broader portfolio. Composition-of-matter patents have begun expiring in certain markets; generic entry and related patent litigation remain important uncertainties.
- Net income increased despite weaker operations because of a $1.119 billion GAAP income-tax benefit. Key items included Swiss tax incentives and a Brazil valuation-allowance release. Swiss incentives generated an estimated net future tax reduction of $831 million; FMC also recorded an approximately $223 million Brazil tax benefit. Adjusted after-tax earnings, which exclude specified tax items and other adjustments, fell about 49%.
- Project Focus, authorized in December 2023, is intended to reduce costs and optimize the company’s footprint and organization. FMC expects total pre-tax restructuring charges of $180–$215 million, including 2023 charges. It targets at least $150 million in annual run-rate savings by year-end 2025 and $50–$75 million of adjusted EBITDA contribution in 2024; savings and execution are not assured.
- For 2024, FMC forecast revenue of $4.50–$4.70 billion, adjusted EBITDA of $900 million–$1.05 billion, and adjusted diluted EPS of $3.23–$4.41. It expected continued destocking, higher inventory costs and modest pricing pressure in the first half, with new-product growth and some market recovery helping in the second half. Forecast free cash flow was $400–$600 million and operating cash flow $670–$850 million. These are non-GAAP or management forecasts; FMC did not provide a GAAP earnings or operating-cash-flow forecast.
Risks, contingencies and unusual items
- Environmental reserves, net of recoveries, totaled $592.1 million; reasonably possible environmental losses exceeded recorded amounts by approximately $240 million. FMC cautioned that ultimate costs could be higher and certain sites’ exposures cannot be reasonably estimated.
- FMC disclosed putative securities class actions alleging misstatements concerning diamide patent protection and enforcement. It intends to defend the cases. It also faced approximately 500 paraquat-related cases, although FMC said it was not aware of ever registering paraquat products in the United States, and approximately 10,976 pending asbestos claims. Asbestos exposure above the reserve could not be reasonably estimated.
- Other key exposures include generic competition and patent challenges, weather and crop conditions, regulatory changes, foreign exchange and geopolitical risks, supply-chain interruptions, customer credit and collections, and the possibility that channel destocking persists. The filing also identifies cybersecurity and environmental-manufacturing risks.
- FMC reported $101.0 million in 2023 currency-related charges, primarily associated with Argentine and Pakistani currency actions, and a separate $25.8 million Argentina PAIS tax charge in cost of sales.
Important facts for investors to verify
- Whether channel inventory levels normalize, and whether shipments recover in line with FMC’s 2024 assumptions.
- Progress against Project Focus costs, timing and savings targets, including any additional charges not yet estimated.
- Cash conversion and working-capital trends, particularly payables, inventory, customer collections and the projected $400–$600 million free-cash-flow range.
- Debt maturities, commercial-paper reliance, covenant headroom and the effect of the repurchase restriction on capital returns.
- Realization and timing of the Swiss and Brazil tax benefits, and the distinction between unusually high GAAP earnings and lower adjusted earnings.
- Generic competition, outcomes of diamide patent proceedings, and changes in environmental reserves or litigation exposure.